The Company reports unaudited total revenue of US$114.9M1 (AU$175.0M) an increase of 18% on
the prior quarter (US$97.1M2 or AU$148.1M). Revenue was primarily generated from sales of Telix’s
prostate cancer imaging product Illuccix®.
U.S. revenue grew by 18% to US$111.8M (US$95.1M in Q4 2023), compared to 11% growth
between Q3 2023 and Q4 2023.
Ann: Telix Q1 2024 Revenue and Business Update, page-2
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.39 |
Change
0.020(0.13%) |
Mkt cap ! $5.085B | |||
| Open | High | Low | Value | Volume |
| $15.54 | $15.82 | $15.26 | $19.08M | 1.228M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 286 | $15.36 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.39 | 1860 | 4 |
View Market Depth
| Last trade - 16.10pm 21/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$15.36 |
Change
0.020 ( 0.07 %) |
||||
| Open | High | Low | Volume | ||
| $15.52 | $15.81 | $15.27 | 132462 | ||
| Last updated 15.59pm 21/05/2024 ? | |||||
| TLX (ASX) Chart |